<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) respond poorly to chemotherapy </plain></SENT>
<SENT sid="1" pm="."><plain>Between 1995 and 2006, 23 pediatric patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> were transplanted with unrelated donor umbilical cord blood (UUCB) at our center </plain></SENT>
<SENT sid="2" pm="."><plain>The median age was 11.1 years (range: 1.1-19.7), median weight was 38.6 kg (range: 9.6-62.6), 61% of patients were male, and median time from diagnosis to transplant was 6.6 months (range: 2.0-61.4) </plain></SENT>
<SENT sid="3" pm="."><plain>Patients were followed for a median of 5.3 years (range: 1.6-12.4 years) posttransplant </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> stage was <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA) in 12, <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) in 8, and <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts in transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>) in 3 patients; 18 (78%) patients had primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain><z:mp ids='MP_0004026'>Monosomy</z:mp> 7 was present in 17(74%) patients </plain></SENT>
<SENT sid="6" pm="."><plain>Patients with <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) were excluded </plain></SENT>
<SENT sid="7" pm="."><plain>Preparative regimen was total body irradiation (TBI) based in 18 (78%) patients </plain></SENT>
<SENT sid="8" pm="."><plain><z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">Graft-versus-host-disease</z:e> (GVHD) prophylaxis was <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> (CsA)/steroids (19 patients) or CsA/<z:chebi fb="0" ids="168396">mycophenolate</z:chebi> mofetil (MMF; 4 patients) </plain></SENT>
<SENT sid="9" pm="."><plain>Grafts were HLA matched at Class I (A and B) at low resolution and Class II (DRB1) at the allelic level, resulting in 16 (70%) 4/6 and 7 (30%) 5/6 matched transplants </plain></SENT>
<SENT sid="10" pm="."><plain>The grafts contained a median of 4.0 x 10(7) (range: 1.7-12.6) total nucleated cells (TNC)/kg precryopreservation; 3.6 x 10(7) (range: 1.0-12.0) TNC/kg and 1.7 x 10(5) (range: 0.2-28.5) CD34+ cells/kg were infused </plain></SENT>
<SENT sid="11" pm="."><plain>Cumulative incidence of neutrophil engraftment (absolute neutrophil count [ANC] &gt;500/microL) at day 42 and day 100 was 73.9% (95% confidence interval [CI] 55.1%-92.7%) and 91.3% (95% CI 71.3%-100.0%) respectively, and that of platelet engraftment (50 K) at 180 days was 69.6% (95% CI 49.8%-89.4%) </plain></SENT>
<SENT sid="12" pm="."><plain>Three patients had graft failure whereas 3 patients (13%) engrafted slowly (after day 42) </plain></SENT>
<SENT sid="13" pm="."><plain>Three patients developed <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD (aGVHD) grades II-IV with a cumulative incidence at 100 days of 13% (95% CI 0.0%-27.1.0%) </plain></SENT>
<SENT sid="14" pm="."><plain>Four patients relapsed with a cumulative incidence of relapse at 3 years of 13.0% (95% CI 0.0%-27.1%) </plain></SENT>
<SENT sid="15" pm="."><plain>Cumulative incidence of nonrelapse mortality (NRM) at 1 year was 27% (95% CI 8.0%-46.0%) </plain></SENT>
<SENT sid="16" pm="."><plain>Ten patients died: 3 graft failure, 4 relapse, 2 infections (1 adenovirus, 1 toxoplasmosis), and 1 Epstein-Barr virus (EBV) <z:hpo ids='HP_0005523'>lymphoproliferative disorder</z:hpo> </plain></SENT>
<SENT sid="17" pm="."><plain>Probabilities of event-free survival (EFS) at 1 and 3 years were 69.6% (95% CI 46.6%-84.2%) and 60.9% (95% CI 38.3%-77.4%), respectively </plain></SENT>
<SENT sid="18" pm="."><plain>Factors associated with better EFS were age &lt; or = 11 years (P = .05) and weight &lt; or = 38 kg (P = .03) </plain></SENT>
<SENT sid="19" pm="."><plain>These results, especially in younger patients with <z:mp ids='MP_0004026'>monosomy</z:mp> 7 positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, are equivalent to published matched allogeneic bone marrow data </plain></SENT>
<SENT sid="20" pm="."><plain>UUCB should be actively considered for pediatric <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients lacking matched related or unrelated adult donors </plain></SENT>
</text></document>